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Objectives: The prevalence of hepatitis is high in emergency department (ED) attendees in the United Kingdom, with a
prevalence of up to 2% for hepatitis B (HBV) HBsAg, and 2.9% for hepatitis C (HCV) RNA. The aim of this paper is to perform an
economic evaluation of opt-out ED-based HCV and HBV testing.
Methods: AMarkovmodelwas developed to analyze the cost-effectiveness of opt-outHCV andHBV testing in EDs in theUK. The
model used data fromUK studies of ED testing to parameterize the HCV and HBV prevalence (1.4% HCV RNA, 0.84% HBsAg), test
costs, and intervention effects (contact rates and linkage to care). For HCV, we used an antibody test cost of £3.64 and RNA test
cost of £68.38, and assumed direct-acting antiviral treatment costs of £10 000. For HBV, we used a combined HBsAg and
confirmatory test cost of £5.79. We also modeled the minimum prevalence of HCV (RNA-positive) and HBV (HBsAg) required
to make ED testing cost-effective at a £20 000 willingness to pay per quality-adjusted life-year threshold.
Results: In the base case, ED testing was highly cost-effective, with HCV and HBV testing costing £8019 and £9858 per quality-
adjusted life-year gained, respectively. HCV and HBV ED testing remained cost-effective at 0.25% HCV RNA or HBsAg
prevalence or higher.
Conclusions: Emergency department testing for HCV and HBV is highly likely to be cost-effective in many areas across the UK
depending on their prevalence. Ongoing studies will help evaluate ED testing across different regions to inform testing
guidelines.
Keywords: hepatitis B, hepatitis C, cost-benefit analysis, emergency service hospital, diagnostic tests, routine, mass screening.
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Across Europe there are approximately 29 million people living
with the hepatitis C virus (HCV) or hepatitis B virus (HBV).1 These
individuals are often asymptomatic in the early stages of infection,
with disease progression leading to liver complications including
cirrhosis, hepatocellular carcinoma, and liver failure, andeventually
causing death.2,3 Despite the United Kingdom having a lower esti-
mated prevalence of HCV and HBV compared with the European
average, there are approximately 210 000 individuals living with
HCV (0.3% among the general population) despite curative direct-
acting antiviral (DAA) treatments available, and an estimated 440
000 individuals living with HBV (0.7% among the general popula-
tion), with only 19% diagnosed.4–6
The United Kingdom has adopted the World Health Organiza-
tion targets to eliminate viral hepatitis as a major public health
threat by 2030, which includes diagnosing 90% of cases andss correspondence to: Jack Williams, MSc, London School of Hygiene & Trop
ail: jack.williams@lshtm.ac.uk
15 - see front matter Copyright ª 2020, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/licproviding treatment to 80% of diagnosed individuals (where
eligible).7 Moreover, with DAA treatments for HCV achieving high
cure rates (sustained virological response [SVR]) at decreasing pri-
ces, and generic HBV treatments now available, there is consider-
able scope for case-finding activities to be cost-effective.7–9
In Europe, current recommendations for HCV and HBV case-
finding activities are largely risk-based, with routine testing
limited to settings attended by high-risk populations, such as drug
treatment services, prisons, and sexual health centres.10,11 HBV
testing is also routinely performed in antenatal services to prevent
mother-to-child transmission.11 Emerging UK evidence suggests
an additional setting for HCV and HBV case-finding is emergency
departments (EDs), as the prevalence of viral hepatitis tends to be
higher among ED attendees (up to 2.9% HCV RNA, and 2% HBV
HBsAg) compared with the general population, as a result of
higher attendance rates among marginalized communities.5,12–17
In 2019, 25.6 million people attended EDs in England, withical Medicine, 15-17 Tavistock Place, London, England, United Kingdom WC1H
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
enses/by-nc-nd/4.0/).
1004 VALUE IN HEALTH AUGUST 2020approximately 40% receiving blood tests as part of their routine
care, providing a valuable opportunity for bloodborne virus (BBV)
testing.14,15,18 The National Institute for Health and Care Excellence
(NICE) currently recommends HIV testing in EDs for areas with
prevalence of $0.2%.19 Nevertheless, there is currently no equiv-
alent UK guidance for HCV or HBV testing in EDs owing to a lack of
cost-effectiveness evidence, although NICE did recently highlight
ED testing as an area of interest for its next surveillance point.20
The aim of this article is to perform a cost-effectiveness anal-
ysis of opt-out ED-based HCV and HBV testing and linkage to care
for all individuals over age 16, and to consider the prevalence
thresholds above which this intervention may be cost-effective in
the United Kingdom.
Methods
Model Analysis and Decision Problem
Wedeveloped adecisionmodel to analyze opt-outHCVandHBV
testing, performed for all individuals attending theEDand receiving
a blood test (as part of routine care) who did not opt out of hepatitis
testing. Emergency department testing for HCV and HBV was
comparedwith no ED testing, which consisted of a background rate
of hepatitis testing, occurring in other settings, only. Opting out of
testing involved the patient declining testingwhen informedby the
clinician that a viral hepatitis test would be performed. As there are
no shared costs between the 2 tests, the model considered opt-out
testing of HCV and HBV separately, both compared with no imme-
diate testing. The decision model consists of a decision tree, with
HBV and HCV testing options, which feed into 3 distinct state
transition Markov models representing chronic HBV, chronic HCV,
and no infection.We assumed all individuals started at an age of 45
years based on data of BBV testing in EDs from the UK.14,15 For each
Markovmodel, patients move between discrete health states using
an annual cycle length. The analysis was performed from the
perspective of the UK National Health Service (NHS), and all results
arepresented inpounds (£, GBP) for 2017.Outcomesweremeasured
in quality-adjusted life-years (QALYs). A lifetime time horizon was
used, and all costs and outcomes were discounted at 3.5%, as per
NICE guidelines.21 Results are presented as incremental cost effec-
tiveness ratios (ICERs) per QALY gained.
Model Structure and Parameterization
To capture the impact of the intervention, we identified 3 UK
studies of ED-based HCV and HBV testing and linkage to care. We
included 2 studies that performed testing and reflex (ie, same
sample) confirmatory testing, with ED-based linkage to care.14,15
We did not include a study that performed ED testing without
reflex confirmatory testing, because individuals from this study
were required to return to a local sexual health service for
confirmatory testing, before being linked to care.22
Model Structure
A decision tree was developed to determine the impact of the
intervention on testing and subsequent linkage to care. It captured
the following: outcome of test (HBsAg1, HCV RNA1, negative),
diagnosis status (new diagnosis vs previously known diagnosis),
proportion of patients contacted after a positive diagnosis, and the
probability of attendance to referral. The proportion of patients
receiving treatment was captured in the HCV model. For the HBV
model, the model captures the proportion of individuals that
engage in care, as not all individuals identified will require im-
mediate treatment. The model structures are shown and describedin Appendix Figures 1-4 in the Supplementary Materials found at
https://doi.org/10.1016/j.jval.2020.03.014.
For individuals with HCV, an estimated 54.5% of new ED di-
agnoses thatwere successfully contactedwere current- or ex-people
who inject drugs (PWID).14 Risk factor informationwas not available
for patients who were not contacted. A lower proportion repre-
senting only current-PWIDs (27.3%) was also considered.14 For HCV-
infected PWIDs, the disease progression, reinfection rate, and back-
ground risk ofmortality differed comparedwith non-PWIDs.We did
not consider PWID status in the HBV model because this was not
reported as a risk factor in the same ED study.14 The model did not
capture the benefit associated with reduced onward transmission
after treatment. Nor did the model consider the potential for HCV/
HBV coinfection to occur in patients, as this was rare across patients
in both ED testing studies (,1% of those testing positive).14,15
Prevalence
The combined prevalence from the included studies was 1.4%
HCV RNA prevalence (132/9423) and 0.84% HBsAg prevalence (80/
9476).14,15 One ED study reported HCV antigen prevalence; how-
ever, we assumed these would be RNA positive. These were varied
in threshold sensitivity analyses to estimate the minimum prev-
alence thresholds at which the intervention remains cost-
effective, since BBV prevalence varies geographically (ranging
from 0.6%-2.9% for HCV and 0%-2% for HBV across UK studies).14–17
We also performed a sensitivity analysis of testing by age
group (16-29, 30-49, 50-69, 701) using stratified prevalence es-
timates.14,15 Other model parameters were assumed to remain
unchanged due to a lack of age-specific data (see Appendix Table 6
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
020.03.014).
Linkage to care
For individuals testing positive in the ED, from the 2 included
studies we derived the proportion that were successfully con-
tacted (contact rate), the proportion requiring linkage to care
(defined as those not previously diagnosed, or those previously
diagnosed but not currently linked to care), the proportion
attending their referral after being contacted, and the proportion
engaging in care.14,15 Different linkage to care parameters were
explored in sensitivity analyses.
For those testing HCV RNA positive, it was estimated that 49.5%
would require linkage to care (new diagnoses, or known diagnoses
disengaged with care), of which 64.7% would be successfully
contacted. Of those contacted, 90.3% would attend at least 1 clinic
appointment, of which 85.7% would engage in care. We assumed
that all HCV patients engaged in care would receive DAA
treatment.
Of those testing HBsAg positive, it was estimated that 52.4%
would require linkage to care, of which 64.7% would be success-
fully contacted. Of those contacted, 90.3% would attend at least 1
clinic appointment, of which 85.7% would engage in care. Patients
engaged in care were assumed to receive treatment if indicated,
(ie, in active disease or cirrhotic health states).
Treatment and outcomes
For HCV, individuals received DAA treatment, with SVR rates
(91%-93%) derived from a UK national cohort.23 There were no
treatment restrictions for PWID, as per current NHS policy. We
assumed those not achieving SVR with their first treatment would
be re-treated once.
For HBV, treatment was assumed to be provided to those
presenting with active disease, and all patients with cirrhosis,
ECONOMIC EVALUATION 1005based on NICE guidelines.24 Various clinical studies informed the
treatment outcomes for HBV, and NICE guidelines informed
treatment stopping rules (based on HBeAg status and cirrhosis),
with full details provided in the Appendix in Supplemental Ma-
terials found at https://doi.org/10.1016/j.jval.2020.03.014.24–29 In
summary, individuals were assumed to be treated with peginter-
feron alfa-2a (PegIFNa) and tenofovir disoproxil fumarate (TDF),
and 13% of HBeAg-positive and 1% of HBeAg-negative individuals
received emtricitabine alongside TDF, based on 1 clinical study
used in our analysis.26 Treatment aims to achieve HBsAg sero-
conversion, or HBeAg seroconversion (for HBeAg-positive in-
dividuals) or inactive disease (for HBeAg-negative individuals).
We also performed a sensitivity analysis in which TDF was the first
and only treatment used, without PegIFNa. We modeled the
likelihood that some HBV patients will disengage from treatment
over time as has been observed in long-term studies of patients on
HBV treatment (Table 1). This is to remain conservative regarding
the benefit associated with identifying new HBV patients, as was
assessed in a sensitivity analysis.
Transition probabilities
Transition probabilities capturing disease progression from
early disease health states up to the compensated cirrhosis health
state were derived from a meta-regression of HCV progression
rates.30 Equivalent transitions for those identified as PWIDs with
HCV were derived from a study estimating PWID disease pro-
gression.31 For compensated cirrhosis and more advanced states, a
previous health technology assessment (HTA) was used for tran-
sitions between health states.32
For HBV, HBeAg status-specific transition probabilities were
derived from a previous HTA performed in the United Kingdom, and
havebeenused for previous economicmodels.33,34 For all individuals
in the model receiving treatment, there was no risk of HBV-related
mortality (until they progressed beyond compensated cirrhosis), as
mortality is comparable to the general population.35 Details on HBV
transitionprobabilitiesare available in theAppendixTables2 and3 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2020.
03.014.
For bothmodels, a background rate ofmortality derived fromUK
life tables was applied to all health states, in addition to mortality
associated with disease progression.36 For PWIDs, a standardized
mortality ratio of 7.8 was applied to background mortality, with
injecting drug use assumed to cease after 11 years (Table 1).37,38
Background rate of testing
The annual background probability of testing was derived from
Public Health England sentinel surveillance of BBV laboratory di-
agnoses, with 40% estimated coverage in the population, esti-
mated from UK national population data.36,39 The annual HCV
testing probability (considering testing from all settings) was
calculated as 1.9%, whereas the annual HBV testing probability,
derived from non-antenatal screening tests, was 2%.
The probability of testing is likely to be higher for those
currently infected, since the yield of positive tests across the UK
observed in national statistics (1.4% for HCV and 1% for HBV) dif-
fers from prevalence among testers in the ED setting.39 We
adjusted the prevalence yield among background testing to ac-
count for the higher likelihood of testing in infected versus un-
infected individuals to match the prevalence observed in national
statistics.
For patients receiving background testing, it was assumed that
the probability of referral and engaging in care was the same as forthose individuals successfully contacted as part of the
intervention.
Utilities
For HCV, utility values for fibrosis and cirrhosis were derived
from a UK RCT.40 Pre-cirrhotic HBV utility values were derived
from a previous economic evaluation, and subsequently used in a
UK HTA.34,41 Hepatitis B virus cirrhosis utility was assumed to be
the same as HCV cirrhosis.40 Utility values for advanced liver
disease, for both HBV and HCV, were derived from a UK study of
transplant patients.42 A sensitivity analysis was performed
considering a lower utility for PWIDs, using an alternative data
source (maximum utility of 0.57, and therefore no utility benefit
associated with achieving SVR).43,44
Costs
Hepatitis C virus test costs were derived from another ED
testing study from London.22 Both included studies performed an
initial antibody test (£3.64), but confirmatory testing differed; one
used a reflex RNA test14, wheras the other performed a reflex HCV
antigen test.15 The model assumed confirmatory RNA testing
(£68.38) was performed for those testing antibody positive.22 For
HBV, we assumed a HBsAg test was initially performed, followed
by a confirmatory reflex HBsAg neutralization assay, with a com-
bined cost of £5.79, derived from a London hospital (Guy’s and St
Thomas’ NHS Trust, personal email communication, November
2017). We assumed the same test costs for individuals receiving
background testing. Because tests were performed on routinely
collected blood samples, costs for retrieving blood were not
included. The model assumes all diagnostic and confirmatory tests
were 100% accurate.
The time required to contact patients was reported by one ED
study to be 15.7 minutes for HCV and 6.7 minutes for HBV, and we
assumed an additional 10 minutes for administration activities.14
We assumed this was performed by a hospital nurse.45 The contact
costs were applied to all individuals testing positive. Background
testing could occur in various settings but was assumed to be the
cost of a general practitioner appointment (£31).45 A lower hy-
pothetical cost (£10) was also considered, since testing could occur
in other healthcare settings, with lower costs compared with a
general practitioner appointment.
National Health Service DAA treatment costs are confidential,
but may be as low as £5000 per course of treatment.8 Due to
uncertainty, we assumed costs of £10 ,000 for DAA treatment, and
£15 000 for re-treatment, incurred only upon SVR, as per NHS
policy.46 Hospital outpatient visits prior to treatment and outpa-
tient treatment monitoring costs were applied (Table 2).47 We
show results across DAA costs of £0 to £35,000 in a sensitivity
analysis (see Appendix Figure 7 in Supplemental Materials found
at https://doi.org/10.1016/j.jval.2020.03.014).
Hepatitis B virus treatment costs were derived from the British
National Formulary. The cost of 48 weeks of PegIFNa was £3672,
assumed for 1 annual cycle.48 The NHS is using generic TDF, with
an estimated annual cost of £578.9,48,49 For those receiving TDF
with emtricitabine, the annual cost was £1299.26,48 Treatment
monitoring costs for HBV were assumed to be captured in health
state costs.
Health state costs were derived from previous HTAs for HBV
and HCV.32,33,45 Individuals who were undiagnosed or diagnosed
but not engaged in care were assumed to not accrue health state
costs until they are diagnosed or reach decompensated cirrhosis
or hepatocellular carcinoma health states.
Table 1. Base case decision parameters for intervention effects.
Base case probabilities Mean value Distribution Source
HCV parameters
Prevalence (RNA1) 1.4% Beta (a = 132, b = 9291) 14,15
Proportion of Ab1 testing RNA1 on reflex test 62.9% Beta (a = 132, b = 78) 14,15
Proportion of diagnoses requiring linkage to care* 49.5% Beta (a = 55, b = 56) 14,15
Proportion contacted 61.8% Beta (a = 47, b = 29) 14,15
Proportion attending referral 85.1% Beta (a = 40, b = 7) 14,15
Proportion receiving treatment, post-referral 62.5% Beta (a = 25, b = 15) 14,15
Background testing probability (annual) 1.9% Beta (a = 347 440, b = 17 645 144) 36,39
Background testing yield (RNA1 prevalence among
testers)
1.4% Beta (a = 4982, b = 342 458) 39
Proportion F0 22.7% Dirichlet (F0,F1,F2,F3,cirrhotic)‡ 14
Proportion F1 22.7% Dirichlet (F0,F1,F2,F3,cirrhotic)‡ 14
Proportion F2 22.7% Dirichlet (F0,F1,F2,F3,cirrhotic)‡ 14
Proportion F3 15.9% Dirichlet (F0,F1,F2,F3,cirrhotic)† 14
Proportion cirrhotic (F4) 15.9% Dirichlet (F0,F1,F2,F3,cirrhotic)† 14
Proportion current PWID 54.5% Beta (a = 6, b = 11) 14
Standard mortality ratio for IDU (while currently
injecting)
7.8 Normal (95% CI = 5.4-10.8) 37
Duration of injecting (years) 11 Uniform (6, 16) 38
Annual probability of reinfection among PWIDs 19.3% Beta (a = 15, b = 62)‡ 51
HBV parameters
Prevalence (HBsAg) 0.84% Beta (a = 80, b = 9396) 14,15
Proportion of diagnoses requiring linkage to care† 52.4% Beta (a = 33, b = 30) 14,15
Proportion contacted 64.7% Beta (a = 33, b = 18) 14,15
Proportion attending referral 90.3% Beta (a = 28, b = 3) 14,15
Proportion accepting treatment, post-referral (if
indicated)
85.7% Beta (a = 24, b = 4) 14,15
Background testing probability (annual) 2% Beta (a = 355 585, b = 17 636 999) 36,39
Background testing yield (HBsAg prevalence
among testers)
1% Beta (a = 3543, b = 352 042) 39
Proportion with inactive disease (HBeAg1
seroconverted or HBeAg- inactive disease)
80% Beta (a = 80, b = 20) 52
Proportion HBeAg1 14.5% Beta (a = 71, b = 419) 52
Proportion cirrhotic (of those with active disease) 12% Beta (a = 3, b = 22) 14
Annual loss to follow-up from treatment 3.3% Uniform (1.7%, 5.0%) 28
CI indicates confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, injecting drug user; PWID, people who inject drugs.
*New diagnosis or known diagnosis not currently engaged in care.
†Sample size of 44, Dirichlet(10,10,10,7,7).
‡Annual probability calculated from 0.906 years mean follow-up (per person).
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We performed probabilistic sensitivity analysis with values for
each parameter sampled simultaneously from their distributions,
and 10 000 individual simulations being performed (distributions
available in Tables 1-2, and Appendix Tables 1-5 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2020.03.014).
Lastly, threshold analyses were undertaken to determine the
minimum prevalence at which the intervention is cost-effective at
a willingness-to-pay (WTP) threshold of £20 000 per QALY. We
also performed threshold analyses for the prevalence required for
cost-effectiveness across a range of patient contact rates and test




Under the base-case settings, testing for HCV and HBV were
both highly cost-effective. The ICER for HCV testing was £8019 per
QALY, and for HBV testing was £9858 per QALY (Table 3). At a WTP
of £20 000 per QALY, the threshold analysis suggested testing for
both HCV and HBV would be cost-effective at 0.25% or higher(Fig. 1). For both HCV and HBV, the ICER reduced and then pla-
teaued at higher prevalence estimates, although was never cost
saving.
Deterministic Sensitivity Analyses
Hepatitis C virus and HBV testing remained cost-effective un-
der all deterministic analyses, with the maximum ICER less than
£12 000 per QALY (Fig. 2). For HCV, the ICER was sensitive to the
cost of DAA treatment, the proportion of individuals tested that
are current PWIDs, and the utility values for PWIDs. For both HCV
and HBV testing, the results were also sensitive to the cost of the
diagnostic test used, and the proportion of individuals requiring
linkage to care. The results were somewhat sensitive to the pro-
portion accepting treatment once referred and the proportion of
diagnosed patients successfully contacted. The cost of contacting
patients and the cost of background appointments had very little
impact on the ICER for either HCV or HBV.
When considering ED testing by age, testing was highly cost-
effective for those aged 16 to 69, but most cost-effective in
those aged 30 to 69, with ICERs below £10 000 for both testing
strategies. For those aged over 70 years (assuming a mean age of
80), the ICERs increased to £21 569 per QALY for HCV testing and
£18 766 per QALY for HBV testing.
Table 2. Intervention and linkage to care costs.
Costs Mean cost Distribution Reference
HCV
HCV antibody test £3.64 Uniform (£2.91, £4.37) 22
HCV RNA test £68.38 Uniform (£54.70, £82.06) 22
DAA treatment £10 000 N/A 8
DAA retreatment £15 000 N/A 8/assumption
Outpatient evaluation £238 Uniform (£190.40, £285.60) 47
Further outpatient evaluation £262 Uniform (£209.60, £314.40) 47
DAA treatment monitoring £1310 Uniform (£1048, £1572) 47
HBV




PegIFNa (annual) £3672 N/A 48
TDF (annual) £578 N/A 48
TDF 1 emtricitabine (annual) £1299 N/A 48
Outpatient evaluation £238 Uniform (£190.40, £285.60) 47
Further outpatient evaluation £262 Uniform (£209.60, £314.40) 47
Contact costs (HBV and HCV)
Cost per HCV contact* £15.85 Uniform (£7.92, £23.77) 14,45
Cost per HBV contact* £10.30 Uniform (£5.15, £15.45) 14,45
Cost of appointment (background testing) £31.30 Uniform (£15.65, £46.95) 45
DAA indicates direct-acting antiviral; HBV, hepatitis B virus; HCV, hepatitis C virus; N/A, not applicable; PegIFNa, peginterferon alfa-2a; TDF, tenofovir disoproxil fumarate.
*Cost of both successful and unsuccessful contacts.
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In the base-case analysis, HCV testing was 99.1% likely to be
cost-effective, and HBV testing 98.4% likely to be cost-effective, at
a WTP of £20 000 per QALY.
We also evaluated the probability that the intervention is cost-
effective at different HCV and HBV prevalence. At HCV RNA and
HBsAg prevalence of 0.5%, testing remained highly likely to be
cost-effective for both, with HCV testing 94% likely, and HBV
testing 95% likely to be cost-effective. At a prevalence of 0.3%,
testing remained likely to be cost-effective for both strategies, but
with less certainty (70% and 71% likely cost-effective for HCV and
HBV testing, respectively). At a lower 0.2% prevalence, testing was
unlikely to be cost-effective for either strategy, with a HCV testing
23% likely to be cost-effective, and HCV testing 24% likely to be
cost-effective. Cost-effectiveness acceptability curves showing the
probability of cost-effectiveness across a range of WTP thresholds,
with base case and lower prevalence scenarios for HCV and HBV
available in Appendix Figure 5 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2020.03.014.Table 3. Cost-effectiveness results for HCV and HBV screening per i
Testing Testing option Total costs Tot
HCV No screening £160.68
ED screening £184.47
HBV No screening £90.66
ED screening £114.66
ED indicates emergency department; HBV, hepatitis B virus; HCV, hepatitis C virus; ICDiscussion
To our knowledge, this is the first economic evaluation of ED
testing for HCV and HBV in the United Kingdom and adds to
previous work demonstrating EDs are a viable setting for HCV and
HBV testing in many areas of the United Kingdom.14,15,22 At our
base-case prevalence of 1.4% and 0.8% for HCV (RNA) and HBV
(HBsAg), both testing strategies were highly cost-effective with
ICERs below £10 000 per QALY, and the ICER did not increase
above £12 000 for either testing strategy in any of the determin-
istic sensitivity analyses examined. While our analysis is an early
economic evaluation in the absence of long-term testing data, the
results of our probabilistic analysis suggest that testing remains
highly likely to be cost-effective at 0.5% prevalence for both HCV
and HBV. This compares favorably to the prevalence observed in
recent ED testing studies across the United Kingdom. A recent
study across 4 UK sites reported a pooled prevalence of 1.69% HCV
RNA (range: 0.6%-2.9%), and 0.95% HBsAg (range: 0%-2%),16
whereas other studies in London EDs have reported HCV RNA or





16.4908 £23.79 0.0030 £8019
16.5497
16.5522 £24.00 0.0024 £9858
ER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Figure 1. Incremental cost-effectiveness ratio (ICER) by HCV RNA















HCV indicates hepatitis C virus.
Figure 2. One-way deterministic sensitivity analysis (DSA) for A) HCV
8000
4000
DAA costs (£10,000 to £5,000)
Percentage of current PWIDs (55% to 27%)
Utiliy (PWIDs maximum utility of 0.57)
Cost of HCV antibody test (£3.64 to £2-£8)
Percentage requiring linkage to care (49.5% to 30%-70%)
Percentage accepting treatment post referral (62.5% to 40%-
80%)
Percentage contacted (62% to 4O%-80%)
Cost of RNA test (£68 .38 to £46)
Cost per contact (£15.85 to £7.92-£23 .77)
Cost background appointment (£31.30 to £10)
Percentage requiring linkage to care (52% to 30%-70%)
Cost of HBV assay (£5.79 to £3-£10)
Percentage acceptIng treatment post referral (85.7% to 70%-
90%)
Percentage contacted (65% to 45%-85%)
Annual loss to follow-up (3 .3% to 0-6.6%)
First year of treatment (PegIFNα to TDF)
Cost per contact(£10.30 to £5.15-£15.45)
Cost background appointment (£31.30 to £10)
A
B
HBV indicates hepatitis B virus; HCV, hepatitis C virus.
1008 VALUE IN HEALTH AUGUST 20201.1%.14,15,17 Thus, our study suggests ED testing is likely to be cost-
effective in most UK settings. Furthermore, since the general
population prevalence of HCV and HBV across Europe (1.1% and
0.9%, respectively) is similar to the base-case ED prevalence used
in our analysis, ED testing could be cost-effective in other Euro-
pean settings, and also in other high-income countries with a HCV
and HBV prevalence similar to or higher than the United
Kingdom.6
Our prevalence threshold analysis suggests that ED testing
would remain cost-effective even at low HCV RNA and HBsAg
prevalence among ED attendees (0.25% or higher for both). These
thresholds are similar to NICE recommendations for HIV testing in
EDs in the United Kingdom ($0.2%).19 Nevertheless, there is no
current NICE recommendation for ED testing for HCV and HBV,
citing the absence of effectiveness or cost-effectiveness evidence
for hepatitis testing in this setting in their 2017 review.11 While
the European Centre for Disease Prevention and Controland B) HBV testing.
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ECONOMIC EVALUATION 1009guidelines recommend HCV and HBV testing in EDs with inter-
mediate or high prevalence ($2%), they do not cite any evidence
for these much higher prevalence thresholds compared to our
estimates.10 While our prevalence threshold estimates provide
guidance for the cost-effectiveness of ED-based HBV and HCV
testing and linkage to care, further studies of ED testing would be
of value to reduce the uncertainty at these thresholds, particularly
as they will be sensitive to other model parameters that may differ
from those used in our base-case analysis.
Our results also suggested that the cost-effectiveness of testing
those aged 70 and above is uncertain, due to lower prevalence and
lower life expectancy from the point of treatment. Nevertheless,
further analyses are required to assess this in more detail owing to
the limitations of the data available for this analysis.
Limitations
Our analysis is based on 2 non-controlled, observational
studies from the United Kingdom, which have considerable limi-
tations. The studies were either short in duration, or with a low
uptake of hepatitis testing among eligible blood samples. Evans
et al undertook 6 weeks of testing, with 56% testing uptake,
whereas Parry et al undertook 9 months of testing, but with only
25% testing uptake. For this reason, our analysis does not evaluate
how long testing should be implemented. The prevalence
threshold results estimate the minimum prevalence required for
the intervention to remain cost-effective, although this assumes
that other parameters remain constant.
In addition to prevalence, early evidence suggests other pa-
rameters included in our model differ across ED departments,
such as the type and sequence of tests performed and their costs,
the proportion of individuals in the population that require link-
age to care, and the effectiveness of contacting those testing
positive.50 These parameters influenced the estimated ICERs, and
while they did not change the base case cost-effectiveness, they
are likely to influence the prevalence thresholds for cost-
effectiveness. Another limitation was the lack of detailed cost
data relating to the intervention. Although the results of the
sensitivity analyses showed this had little impact upon our results,
we did not include staff training costs or incentives to increase
testing rates that have been previously reported.22 The interven-
tion consists of a number of individual parts, including the initial
test, informing the patient of the result, and linking individuals to
care following a positive diagnosis. Although the model in-
corporates all of these components, we acknowledge that they are
separate factors and that there are many ways in which they could
be individually optimized.
Lastly, our model did not capture the potential prevention
benefit associated with a reduction in onward transmission
among PWIDs with HCV who achieve SVR, and thus likely un-
derestimates the impact of HCV testing.Conclusion
Although there is uncertainty regarding many of the parame-
ters, our results suggest that ED-based HCV and HBV testing and
linkage to care is highly cost-effective at our base-case prevalence.
Moreover, the sensitivity analyses strongly suggest that this
conclusion is robust. At a lower 0.5% prevalence, HCV and HBV
testing remained highly likely to be cost-effective. This suggests
the introduction of ED testing is likely to be cost-effective for
many areas of the United Kingdom, since most ED-based HCV and
HBV prevalence estimates from the United Kingdom exceed
this.14–16 Nevertheless, there is uncertainty around the prevalencethresholds at which HCV and HBV testing becomes cost-effective,
although our analysis shows it is likely to be low.
Although our results suggest implementation of ED testing
should be performed even in areas with a relatively low preva-
lence, interventions should be evaluated at a local level, using
local data to inform key parameters and identify which of these
context-specific parameters influence cost-effectiveness. Lastly,
budget impact analyses using local data will be helpful for plan-
ning in areas introducing ED testing. These analyses will help
reduce the uncertainty in our results and provide data to inform
local healthcare decision-making bodies.Supplemental Material
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